- Home
- GNTY vs ZBIO Comparison
GNTY vs ZBIO Comparison
Compare GNTY & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTY
- ZBIO
- Stock Information
- Founded
- GNTY 1913
- ZBIO 2019
- Country
- GNTY United States
- ZBIO United States
- Employees
- GNTY N/A
- ZBIO N/A
- Industry
- GNTY Major Banks
- ZBIO
- Sector
- GNTY Finance
- ZBIO
- Exchange
- GNTY Nasdaq
- ZBIO NYSE
- Market Cap
- GNTY 434.5M
- ZBIO 389.2M
- IPO Year
- GNTY 2017
- ZBIO 2024
- Fundamental
- Price
- GNTY $41.45
- ZBIO $11.12
- Analyst Decision
- GNTY Buy
- ZBIO Strong Buy
- Analyst Count
- GNTY 2
- ZBIO 7
- Target Price
- GNTY $41.00
- ZBIO $32.29
- AVG Volume (30 Days)
- GNTY 26.0K
- ZBIO 135.6K
- Earning Date
- GNTY 07-14-2025
- ZBIO 06-17-2025
- Dividend Yield
- GNTY 2.42%
- ZBIO N/A
- EPS Growth
- GNTY 18.89
- ZBIO N/A
- EPS
- GNTY 2.91
- ZBIO N/A
- Revenue
- GNTY $123,780,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- GNTY $10.99
- ZBIO $206.00
- Revenue Next Year
- GNTY $4.68
- ZBIO $77.40
- P/E Ratio
- GNTY $14.22
- ZBIO N/A
- Revenue Growth
- GNTY 4.44
- ZBIO N/A
- 52 Week Low
- GNTY $27.99
- ZBIO $5.83
- 52 Week High
- GNTY $43.09
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- GNTY 54.52
- ZBIO N/A
- Support Level
- GNTY $40.00
- ZBIO N/A
- Resistance Level
- GNTY $41.70
- ZBIO N/A
- Average True Range (ATR)
- GNTY 1.02
- ZBIO 0.00
- MACD
- GNTY -0.13
- ZBIO 0.00
- Stochastic Oscillator
- GNTY 46.89
- ZBIO 0.00
About GNTY Guaranty Bancshares Inc.
Guaranty Bancshares Inc is a bank holding company conducting banking activities through its wholly-owned subsidiary. The company provides its customers with a full array of relationship-driven commercial and consumer banking products and services, as well as mortgage, trust, and wealth management products and services that are tailored to meet the needs of small and medium-sized businesses, professionals, and individuals. It also provides other services such as Credit cards, Personal Loans, Business Checking, Treasury Management, and other related services. The company generates its revenue from interest on loans and investments, customer service and loan fees, fees related to the sale of mortgage loans, and trust and wealth management services.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.